NPI: 1902200991 · ALBEMARLE, NC 28001 · Pediatric Adolescent Medicine Physician · NPI assigned 10/20/2014
Authorized official RISSMILLER, SCOTT controls 20+ related entities in our dataset. Read more
| Authorized Official | RISSMILLER, SCOTT (ENTERPRISE EVP) |
| Parent Organization | CAROLINAS PHYSICIANS NETWORK INC |
| NPI Enumeration Date | 10/20/2014 |
Other providers sharing the same authorized official: RISSMILLER, SCOTT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 25,053 | $823K |
| 2019 | 24,885 | $1.02M |
| 2020 | 18,798 | $782K |
| 2021 | 43,560 | $1.09M |
| 2022 | 72,790 | $1.39M |
| 2023 | 91,088 | $1.42M |
| 2024 | 90,477 | $1.20M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34,170 | 29,364 | $2.00M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20,187 | 17,272 | $1.82M |
| 99199 | Unlisted special service, procedure or report | 157,973 | 101,094 | $835K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6,902 | 5,932 | $603K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7,124 | 5,634 | $563K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4,682 | 4,183 | $423K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4,069 | 3,587 | $246K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2,318 | 1,978 | $217K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4,653 | 4,156 | $214K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 11,784 | 9,969 | $208K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 6,880 | 5,736 | $204K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 6,115 | 5,498 | $79K |
| 99215 | Prolong outpt/office vis | 552 | 489 | $70K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 10,870 | 9,302 | $48K |
| 96127 | 9,657 | 8,461 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 580 | 476 | $25K |
| 99460 | 328 | 318 | $21K | |
| 90474 | 1,046 | 862 | $18K | |
| 99238 | Hospital discharge day management, 30 minutes or less | 250 | 246 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 293 | 247 | $12K |
| 87807 | 780 | 669 | $10K | |
| 96161 | 3,349 | 2,688 | $10K | |
| 90651 | 448 | 393 | $7K | |
| 99462 | 231 | 194 | $7K | |
| 90734 | 574 | 504 | $5K | |
| D0145 | Oral evaluation for a patient under three years of age | 220 | 173 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 174 | 172 | $5K |
| 83655 | 300 | 261 | $4K | |
| 92551 | 5,965 | 5,336 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 95 | 84 | $3K |
| 90686 | 3,839 | 3,413 | $3K | |
| 99173 | 9,053 | 8,008 | $2K | |
| 90620 | 60 | 51 | $2K | |
| D1206 | Topical application of fluoride varnish | 219 | 172 | $2K |
| 0002A | 28 | 25 | $2K | |
| 0001A | 36 | 20 | $1K | |
| 95117 | 98 | 52 | $883.34 | |
| 0071A | 14 | 13 | $804.33 | |
| 96160 | 289 | 256 | $778.68 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 79 | 67 | $753.32 |
| 80061 | Lipid panel | 49 | 39 | $638.10 |
| 81003 | 294 | 244 | $613.94 | |
| 90715 | 61 | 56 | $313.80 | |
| 90677 | 510 | 492 | $260.81 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 26 | 26 | $241.29 |
| 90670 | 3,771 | 3,155 | $239.74 | |
| 90633 | 686 | 603 | $108.96 | |
| 86308 | 12 | 12 | $71.38 | |
| 36416 | 233 | 179 | $53.72 | |
| 85027 | 13 | 12 | $47.88 | |
| 85018 | 71 | 65 | $32.27 | |
| 1160F | 9,480 | 8,310 | $0.00 | |
| 1159F | 16,407 | 13,616 | $0.00 | |
| 3078F | 5,143 | 4,560 | $0.00 | |
| 99177 | 112 | 109 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 33 | 25 | $0.00 |
| 90710 | 15 | 15 | $0.00 | |
| 90723 | 2,135 | 1,853 | $0.00 | |
| 90680 | 1,651 | 1,424 | $0.00 | |
| 3074F | 5,311 | 4,692 | $0.00 | |
| 3008F | 1,342 | 1,287 | $0.00 | |
| 90647 | 2,252 | 1,943 | $0.00 | |
| 90656 | 488 | 463 | $0.00 | |
| 90696 | 14 | 14 | $0.00 | |
| 3044F | 216 | 189 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 27 | 26 | $0.00 |
| 3079F | 15 | 14 | $0.00 |